In short
Clinical trials investigating Lovastatin are studying people at risk of cardiovascular disease who may receive statins. The main aim is to evaluate safety, effectiveness, and cost-effectiveness, including whether gene testing can help reduce muscle-related problems from statin treatment.
Key points
- Clinical trials investigating Lovastatin are focused on people at risk of cardiovascular disease who may receive statin treatment. The main study is a Phase 3 trial with 216 participants. It is testing a gene analysis strategy to see if it can reduce statin-related muscle symptoms and related blood test changes. The trial also looks at safety and cost-effectiveness. The study uses a combined outcome that includes muscle symptoms and creatine phosphokinase, or CPK, levels.
Trial overview
This clinical trial is authorised and is designed to study a gene analysis strategy in people at risk of cardiovascular disease who may receive statins. The brief summary says the goal is to assess whether preemptive genotyping can reduce statin-associated musculoskeletal adverse events.
Who is being studied
The trial includes patients at risk of cardiovascular disease who are suitable for high- or moderate-intensity statin treatment. This means the study is focused on people who may need statins as part of their heart and blood vessel risk care.
What is being tested
The main idea being tested is a gene analysis strategy, also described as preemptive genotyping. Genotyping means looking at a person’s genes before treatment to see whether the result can help lower the chance of muscle-related problems from statin therapy.
The study also evaluates safety and cost-effectiveness. Cost-effectiveness means whether the strategy gives useful results for the money spent.
Trial phase and size
This is a Phase 3 study with an enrollment of 216 participants. Phase 3 trials usually study a treatment strategy in a larger group to better understand how well it works and how safe it is, and this trial follows that pattern.
Main outcomes being measured
The primary outcome is a combined measure that includes clinically relevant statin-associated musculoskeletal symptoms or a serum CPK level greater than three times the upper limit of normal for each site’s laboratory. A musculoskeletal symptom is a problem affecting muscles, bones, or joints, and CPK is a blood marker that can rise when muscle is injured or irritated.
The musculoskeletal symptom part of the outcome is defined using two scores: a SAMS-CI score of 7 or higher and an NPRS score of 3 or higher. These are scoring tools used to measure how likely symptoms are related to statin treatment and how strong the pain is.
Statin options listed in the trial
Although the trial focuses on Lovastatin in the overall article topic, the source record lists several statins used in the study plan. These include rosuvastatin, pravastatin, pitavastatin, simvastatin, fluvastatin, lovastatin, and atorvastatin.
- Rosuvastatin and atorvastatin are listed as treatment options in the trial record.
- Pravastatin, pitavastatin, simvastatin, and fluvastatin are also included in the intervention list.
- Lovastatin appears directly in the intervention list as one of the statin treatments being considered.